These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 23178991)

  • 1. IBS and the role of otilonium bromide.
    Boeckxstaens G; Corazziari ES; Mearin F; Tack J
    Int J Colorectal Dis; 2013 Mar; 28(3):295-304. PubMed ID: 23178991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of anti-spasmodics in the treatment of irritable bowel syndrome: focus on otilonium bromide.
    Forte E; Pizzoferrato M; Lopetuso L; Scaldaferri F
    Eur Rev Med Pharmacol Sci; 2012 Jan; 16(1):25-37. PubMed ID: 22338545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome.
    Clavé P; Acalovschi M; Triantafillidis JK; Uspensky YP; Kalayci C; Shee V; Tack J;
    Aliment Pharmacol Ther; 2011 Aug; 34(4):432-42. PubMed ID: 21679214
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irritable bowel syndrome.
    Spinelli A
    Clin Drug Investig; 2007; 27(1):15-33. PubMed ID: 17177577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Irritable bowel syndrome: focus on otilonium bromide.
    Boeckxstaens G; Clavé P; Corazziari ES; Tack J
    Expert Rev Gastroenterol Hepatol; 2014 Feb; 8(2):131-7. PubMed ID: 24417261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of antispasmodics in the treatment of irritable bowel syndrome.
    Annaházi A; Róka R; Rosztóczy A; Wittmann T
    World J Gastroenterol; 2014 May; 20(20):6031-43. PubMed ID: 24876726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of herbal extract granules combined with otilonium bromide on irritable bowel syndrome with diarrhoea: a study protocol for a randomised controlled trial.
    Kim JI; Kim P; Lee JH; Kim YJ; Yang NR; Baeg MK; Choi JS; Kim HJ; Kim J; Sunwoo YY; Lee JH; Ha H; Park TY
    BMJ Open; 2017 Dec; 7(11):e018362. PubMed ID: 29196484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome.
    Evangelista S
    Curr Pharm Des; 2004; 10(28):3561-8. PubMed ID: 15579053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Otilonium bromide in irritable bowel syndrome: a dose-ranging randomized double-blind placebo-controlled trial.
    Chmielewska-Wilkoń D; Reggiardo G; Egan CG
    World J Gastroenterol; 2014 Sep; 20(34):12283-91. PubMed ID: 25232263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome.
    Glende M; Morselli-Labate AM; Battaglia G; Evangelista S
    Eur J Gastroenterol Hepatol; 2002 Dec; 14(12):1331-8. PubMed ID: 12468954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Otilonium Bromide treatment prevents nitrergic functional and morphological changes caused by chronic stress in the distal colon of a rat IBS model.
    Traini C; Idrizaj E; Garella R; Faussone-Pellegrini MS; Baccari MC; Vannucchi MG
    J Cell Mol Med; 2021 Jul; 25(14):6988-7000. PubMed ID: 34109728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2007 Oct; (4):CD003960. PubMed ID: 17943807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study.
    Battaglia G; Morselli-Labate AM; Camarri E; Francavilla A; De Marco F; Mastropaolo G; Naccarato R
    Aliment Pharmacol Ther; 1998 Oct; 12(10):1003-10. PubMed ID: 9798806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Irritable bowel syndrome: a clinical review.
    Chey WD; Kurlander J; Eswaran S
    JAMA; 2015 Mar; 313(9):949-58. PubMed ID: 25734736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Otilonium bromide enhances sensory thresholds of volume and pressure in patients with irritable bowel syndrome.
    Czimmer J; Süto G; Király A; Mózsik G
    J Physiol Paris; 2001; 95(1-6):153-6. PubMed ID: 11595430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical and functional evaluation of the efficacy of otilonium bromide: a multicenter study in Italy.
    Baldi F; Longanesi A; Blasi A; Monello S; Cestari R; Missale G; Corazziari E; Badiali G; Pescatori M; Anastasio G
    Ital J Gastroenterol; 1991 Nov; 23(8 Suppl 1):60-3. PubMed ID: 1756285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update on Pharmacotherapy for Irritable Bowel Syndrome.
    Munjal A; Dedania B; Cash B
    Curr Gastroenterol Rep; 2019 Apr; 21(6):25. PubMed ID: 31025114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of irritable bowel syndrome.
    Trinkley KE; Nahata MC
    J Clin Pharm Ther; 2011 Jun; 36(3):275-82. PubMed ID: 21545610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on Eluxadoline for the Treatment of Irritable Bowel Syndrome with Diarrhea: Patient Selection and Perspectives.
    Liu R; Staller K
    Drug Des Devel Ther; 2020; 14():1391-1400. PubMed ID: 32308371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tegaserod for the treatment of irritable bowel syndrome.
    Evans BW; Clark WK; Moore DJ; Whorwell PJ
    Cochrane Database Syst Rev; 2004; (1):CD003960. PubMed ID: 14974049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.